Post-ischemic stroke motor dysfunction
Conditions
Interventions
Acupuncture group: The point selection is according to "Xingnao Kaiqiao" acupuncture theory:Neiguan (bilateral), Shuigou, Sanyinjiao (affected side), Fengchi, Wangu, Tianzhu, Xiajiquan, Chize, Hegu, a
Sham acupuncture group:Non-meridian non-acupoints (control points) are selected for shallow insertion of 0.2-0.3 cun (4-6 mm). The needle is hanging at the skin without sensation of "De Qi", and no ac
Sponsors
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Meets the diagnostic criteria for ischemic stroke: diagnosis refers to the "2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke" designated by the American Heart Association/American Stroke Association (AHA/ASA); (2) Age 45-75 years, gender (referencing previously published JAMA Network Open); (3) Within 0-14 days of ischemic stroke onset; (4) Presence of motor dysfunction, modified Rankin scale (mRS) score of 2-4; (5) Understands and follows clinical trial procedures, voluntarily participates and signs the informed consent form (can be signed voluntarily by the individual or their guardian).
Exclusion criteria
Exclusion criteria: (1) Subjects with intracranial hemorrhage shown on CT/MRI imaging or those presenting with signs of subarachnoid hemorrhage; (2) Subjects with a history of stroke, or those with other causes of motor dysfunction, or those with a pre-stroke mRS score > 2; (3) Subjects with cerebral infarction accompanied by severe cerebral edema, mass effect, and signs of brain herniation; (4) Subjects with NIHSS consciousness level score (1a) > 2, or those with epilepsy, dementia, schizophrenia, or other conditions severely impairing cognitive function and mental awareness, making them unable to cooperate with treatment or evaluation of efficacy; (5) Subjects with bleeding or oozing after thrombolysis or thrombectomy; (6) Subjects with severe liver dysfunction, including liver failure, cirrhosis, portal hypertension (esophageal varices), and active hepatitis; subjects with heart failure, bacterial endocarditis, pericarditis, or acute pancreatitis; subjects with renal dysfunction (nephritis, nephropathy, and renal failure, etc.); subjects with intracranial tumors, arteriovenous malformations, aneurysms, or other major diseases; (7) Subjects with a life expectancy of less than one year due to malignant diseases or other severe illnesses; (8) Subjects with local infection at acupuncture points; (9) Pregnant or breastfeeding women, or those with plans to conceive who are unwilling to take effective contraceptive measures; (10) Subjects currently participating in or who participated in other clinical studies within the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Rankin Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| National Institutes of Health Stroke Scale;Barthel Index;Fugl-Meyer Assessment Scale;Carroll upper extremity function test; | — |
Countries
China
Contacts
Public ContactShi Jiang Wei
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Outcome results
None listed